NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis
Status:
Unknown status
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
To improve the treatment outcome in patients with tuberculosis and integrate the
pharmacogenetics into clinical practice, the information of NAT2 genotyping was used in
re-challenge protocol for isoniazid (INH) titration in patients with anti-tuberculosis
medication-induced hepatitis.